Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00185250
Status:
COMPLETED
Last Update Posted:
2008-12-19
First Post:
2005-09-10
Brief Title:
Betaferon Betaseron Interferon Beta-1b in Patients With Chronic Viral Cardiomyopathy
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
Double-Blind Placebo-Controlled Randomized Parallel Group Multicenter Study to Evaluate Efficacy and Safety of 4 and 8 Million Units BetaferonBetaseron Interferon Beta-1b Given Subcutaneously Every Other Day Over 24 Weeks in Patients With Chronic Viral Cardiomyopathy
Status:
COMPLETED
Status Verified Date:
2008-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Chronic viral cardiomyopathy is a disease where the cardiac muscle is attacked by a virus and this may result in a reduction in the output of the heart pump function thereby causing complaints such as chest pain shortness of breath and palpitations
Betaferon interferon beta-1b is marketed for the treatment of Multiple Sclerosis already but until now it has not been proven whether it is also effective in patients with chronic viral myocardial disease
This study will be conducted to examine the efficacy and safety of Betaferon in patients with this disease The aim of the treatment is to eliminate the virus from the heart so that the heart function and clinical status can gradually improve
Betaferon interferon beta-1b is marketed for the treatment of Multiple Sclerosis already but until now it has not been proven whether it is also effective in patients with chronic viral myocardial disease
This study will be conducted to examine the efficacy and safety of Betaferon in patients with this disease The aim of the treatment is to eliminate the virus from the heart so that the heart function and clinical status can gradually improve
Detailed Description:
The study has previously been posted by Schering AG Germany Schering AG Germany has been renamed to Bayer Schering Pharma AG Germany
Bayer Schering Pharma AG Germany is the sponsor of the trial
Bayer Schering Pharma AG Germany is the sponsor of the trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 305852 | None | None | None |